BIOD-250

BIOD-250 is an ultra-rapid-acting formulation of insulin lispro, originally developed by Biodel Inc. for the management of postprandial glucose in patients with diabetes mellitus. The formulation utilizes Biodel's proprietary technology, incorporating ethylenediaminetetraacetic acid (EDTA) and citrate as excipients to accelerate the absorption of insulin lispro from the subcutaneous injection site. These excipients promote the dissociation of insulin hexamers into rapidly-absorbed monomers, thereby achieving a faster onset of action and a more rapid decline in insulin levels compared to standard rapid-acting analogs like Humalog. In Phase 1 clinical trials, BIOD-250 demonstrated pharmacokinetic profiles that more closely mimic the physiological insulin response to a meal. Following Biodel's merger with Albireo Pharma in 2016, the development of this program was deprioritized and subsequently discontinued.